Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kontafarma China HoldingsHKSE:01312 +3.45% Market Cap is HK$167.7 Mil as of Aug. 07, 2026. The stock has 3 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Kontafarma China Holdings ranks worse than 79.37% on this metric.
Kontafarma China Holdings's quarterly market cap
increased
from Dec. 2024 (HK$145.3 Mil) to Jun. 2025 (HK$156.5 Mil) and
increased
from Jun. 2025 (HK$156.5 Mil) to Dec. 2025 (HK$162.1 Mil).
Kontafarma China Holdings's annual market cap
declined
from Dec. 2023 (HK$201.2 Mil) to Dec. 2024 (HK$145.3 Mil) but then
increased
from Dec. 2024 (HK$145.3 Mil) to Dec. 2025 (HK$162.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kontafarma China Holdings's Enterprise Value for Today is HK$222.7 Mil.
Kontafarma China Holdings (HKSE:01312) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kontafarma China Holdings Market Cap Related Terms
Kontafarma China Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontafarma China Holdings Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Kontafarma China Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontafarma China Holdings (HKSE:01312) has a Market Cap of HK$167.7 Mil as of Aug. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kontafarma China Holdings and its competitors. According to the industry distribution chart, Kontafarma China Holdings ranks #812 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 79.4%.
Is Kontafarma China Holdings' Market Cap too high?
Kontafarma China Holdings' current Market Cap is HK$167.7 Mil. Based on the distribution chart, Kontafarma China Holdings ranks #812 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Kontafarma China Holdings' Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kontafarma China Holdings ranks #812 out of 1023 companies for Market Cap. This places Kontafarma China Holdings in the lower half of its industry. The industry median Market Cap is 219.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 219.20, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kontafarma China Holdings and its competitors. For the Drug Manufacturers industry, the median Market Cap is 219.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kontafarma China Holdings's current Market Cap is HK$167.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 25% below its estimated fair value. The current Market Cap is HK$167.7 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current Market Cap is HK$167.7 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01312 has been successfully added to your 
